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systematic assessment of 
prescribed medications and short-
term risk of myocardial infarction 
– a pharmacopeia-wide association 
study from Norway and sweden
Abhijit sen1,2, Ioannis Vardaxis3, Bo Henry Lindqvist3, Ben Michael Brumpton4,5,6, Linn Beate 
strand1, Inger Johanne Bakken  7, Lars Johan Vatten1, Pål Richard Romundstad1, Rickard 
Ljung8, Kenneth Jay Mukamal9 & Imre Janszky1,10
Wholesale, unbiased assessment of Scandinavian electronic health-care databases offer a unique 
opportunity to reveal potentially important undiscovered drug side effects. We examined the short-
term risk of acute myocardial infarction (AMI) associated with drugs prescribed in Norway or Sweden. 
We identified 24,584 and 97,068 AMI patients via the patient- and the cause-of-death registers and 
linked to prescription databases in Norway (2004–2014) and Sweden (2005–2014), respectively. A case-
crossover design was used to compare the drugs dispensed 1–7 days before the date of AMI diagnosis 
with 15–21 days’ time -window for all the drug individually while controlling the receipt of other drugs. 
A BOLASSO approach was used to select drugs that acutely either increase or decrease the apparent 
risk of AMI. We found 48 drugs to be associated with AMI in both countries. Some antithrombotics, 
antibiotics, opioid analgesics, adrenergics, proton-pump inhibitors, nitroglycerin, diazepam, 
metoclopramide, acetylcysteine were associated with higher risk for AMI; whereas angiotensin-II-
antagonists, calcium-channel blockers, angiotensin-converting-enzyme inhibitors, serotonin-specific 
reuptake inhibitors, allopurinol, mometasone, metformin, simvastatin, levothyroxine were inversely 
associated. The results were generally robust in different sensitivity analyses. This study confirms 
previous findings for certain drugs. Based on the known effects or indications, some other associations 
could be anticipated. However, inverse associations of hydroxocobalamin, levothyroxine and 
mometasone were unexpected and needs further investigation. This pharmacopeia-wide association 
study demonstrates the feasibility of a systematic, unbiased approach to pharmacological triggers of 
AMI and other diseases with acute, identifiable onsets.
More than 90% of all US adults aged 65 years and older use at least one prescription medication1, a proportion 
that continues to increase. Adverse and often unanticipated drug reactions are a major public health challenge. 
They are estimated to cost around $30 billion annually in the US alone2.
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Although drugs undergo several phases of testing prior to approval, pre-approval trials are typically just large 
enough to detect the expected effect on physiological outcomes. These trials are commonly too small and of too 
short duration to assess meaningful clinical outcomes3. Pre-approval trials also tend to disproportionately exclude 
women, especially in their reproductive age, patients with comorbidities, individuals in lower socioeconomic 
strata, children, and elderly individuals, all of which limit generalizability of findings4. Thus, an urgent need exists 
for systematic, generalizable monitoring of important clinical effects even in the post-marketing phase. For exam-
ple, rofecoxib and sibutramine were both withdrawn from the market due to increased risk for acute myocardial 
infarction (AMI)5,6.
Although many adverse drug reactions can be anticipated on the basis of a drug’s physiological effects, the 
example of the human genome has illustrated how modest the predictive power of variants in established candi-
date pathways can be. In the case of genomics, this has been addressed by technological improvements that enable 
wholesale, unbiased assessment of millions of genetic variants on a single outcome –genome-wide association 
studies (GWAS). These studies have identified dozens of novel pathways across a variety of endpoints. In the 
case of pharmaceuticals, the advent of registers that track the dispensing of prescription medications enables a 
comparable approach – the pharmacopoeia-wide association study (PWAS) – to perform unbiased assessment of 
literally all prescribed medications. Such an approach could offer the potential to identify drugs that unexpectedly 
increase or decrease risk of serious clinical events with maximal generalizability and statistical power.
To test this approach, we undertook a systematic examination of all potentially existing associations between 
prescribed drugs and short-term risk for AMI using comprehensive nation-wide data from Sweden and Norway. 
Given the very strong likelihood of confounding by indication in pharmacoepidemiology, we focused on 
short-term AMI risk and used case-only methods for self-matching. Because this approach may overestimate the 
effects of drugs used chronically7, it yields estimates that are most reliable for drugs typically taken for short time 
periods (for acute use).
Results
Among a total of 121,652 AMI patients, 97,068 were from Sweden (79,882 and 17,186 identified via the patient 
register and the cause of death register, respectively) and 24,584 were from Norway (20,413 and 4,171 identified 
via the patient register and the cause of death register, respectively). Characteristics of these patients are presented 
in Table 1.
A total of 1262 and 1535 distinct pharmaceutical drugs were dispensed for AMI patients in Norway and 
Sweden, respectively. Out of these, 737 and 1081 unique drugs were dispensed for AMI patients in either the 
case- or control- period, in Norway and Sweden, respectively. Subsequently, a total of 81 and 112 unique drug 
types were selected in Norway and Sweden via BOLASSO procedure, respectively. Finally, a total of 48 drugs 
were selected in common from both countries (Figure 1). Table 2 presents the country-specific and the combined 
estimates of these commonly selected drugs.
Cardiovascular drugs. Several cardiovascular drugs were associated with higher AMI risk, poten-
tially related to their indications for use. These medications included nitroglycerin and different classes of 
antithrombotic agents (ticagrelor, clopidogrel, enoxaparin, acetylsalicylic acid). On the other hand, certain 
angiotensin-II-antagonists (losartan, candesartan), calcium-channel blockers (amlodipine, felodipine), and an 
angiotensin-converting-enzyme inhibitor (ramipril) were associated with lower risk of AMI.
Antibiotics. Use of penicillins, ciprofloxacin, doxycycline, erythromycin, trimethoprim and nitrofurantoin 
were associated with higher risk of AMI. In contrast, metronidazole was associated with lower risk of AMI.
Characteristics Total N (%) Sweden N (%) Norway N (%)
Total AMI patients* 121, 652 97,068 24,584
 Males 65,171 (53.6) 50,583 (52.1) 14,588 (59.3)
Age (in years)
Below 30 65 (0.1) 43 (0.04) 22 (0.1)
30–39 428 (0.4) 256 (0.3) 172 (0.7)
40–49 2836 (2.3) 1785 (1.8) 1051 (4.3)
50–59 9299 (7.6) 6369 (6.6) 2930 (11.9)
60–69 20,597 (16.9) 15,434 (15.9) 5163 (21)
70–79 30,710 (25.2) 24,539 (25.3) 6171 (25.1)
80–89 43,126 (35.5) 36,113 (37.2) 7013 (28.5)
90–99 14,419 (11,9) 12,381 (12.8) 2038 (8.3)
≥100 172 (0.1) 148 (0.2) 24 (0.1)
Table 1. Characteristics of the study sample. *The number reflects the patients who were hospitalized or died 
due to acute myocardial infarction both within and outside hospital. In addition, the numbers reflects the 
patients who dispensed prescribed drugs either in the case-period (1 to 7 days) or control-period (15 to 21 days) 
before the index date for the diagnosis of their AMI in Norway and Sweden, respectively.
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Analgesics. Several opioid analgesics were associated with higher risk of AMI. Of these, morphine in com-
bination with antispasmodics was associated with particularly high risk for AMI. Among non-opioid agents, 
diclofenac was also associated with increased risk for AMI.
Psychoactive medications. Among anxiolytic, antidepressant, and antipsychotic agents, we observed an 
increased AMI risk in association with the use of diazepam. Two serotonin-specific reuptake inhibitors, citalo-
pram and sertraline, were associated with lower risk for AMI.
Other medications. Specific adrenergic agents (terbutaline, salbutamol), proton pump inhibitors (esome-
prazole and omeprazole), metoclopramide and acetylcysteine were associated with higher risk of AMI. On the 
other hand, allopurinol, mometasone, metformin, simvastatin and levothyroxine were inversely associated with 
risk of AMI.
Figure 1. Pharmacopeia-wide case-crossover analysis of dispensed medication data in relation to risk for acute 
myocardial infarction. The above plot illustrates (A) 81 unique drug types which were selected in Norway, (B) 
112 unique drug types which were selected in Sweden, and (C) 48 drugs which were common hits from both the 
countries. Y-axis displays relative risk on the log scale, X-axis displays all the prescribed drugs studied grouped 
according to the Anatomical Therapeutic Chemical (ATC) classification.
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ATC CodeЅ Drug Names
Exposed Case- 
period only
Exposed 
Control- 
period only
Sweden‡
Exposed Case- 
period only
Exposed 
Control- 
period only
Norway§ Total
RR (95% CI) RR (95% CI)
Combined 
estimates RR 
(95% CI)
Narcotic analgesics
N02AG01 Morphine & antispasmodics 256 42 5.92 (4.09–8.57) 28 2 6.66 (2.31–19.36) 6.00 (4.23–8.50)
N02AA01 Morphine 2195 1515 1.69 (1.52–1.89) 137 67 1.84 (1.21–2.79) 1.70 (1.53–1.89)
N02AA05 Oxycodone 2659 2337 1.21 (1.10–1.34) 252 191 1.40 (1.07–1.84) 1.23 (1.12–1.35)
N02AA59 Codeine, combinations 1526 1391 1.09 (1.00–1.20) 1386 1202 1.14 (1.03–1.25) 1.11 (1.04–1.19)
R05FA02 Opium derivatives & expectorant 828 438 1.73 (1.52–1.97) 71 35 1.59 (1.00–2.54) 1.72 (1.52–1.95)
Non-narcotic analgesic
N02BE01 Paracetemol 14481 14036 1.01 (0.75–1.05) 1412 1290 1.02 (0.93–1.12) 1.01 (0.98–1.05)
Anti-inflammatory drug
M01AB05 Diclofenac 1180 1001 1.15 (1.04–1.28) 504 387 1.26 (1.07–1.47) 1.18 (1.08–1.29)
Antibiotics
J01FA01 Erythromycin 90 36 2.14 (1.39–3.30) 156 89 1.66 (1.22–2.24) 1.81 (1.41–2.32)
J01AA02 Doxycycline 1095 591 1.76 (1.58–1.96) 324 213 1.51 (1.25–1.83) 1.70 (1.54–1.86)
J01CA04 Amoxicillin 575 353 1.44 (1.24–1.66) 327 168 2.09 (1.69–2.58) 1.62 (1.44–1.83)
J01XE01 Nitrofurantoin 365 249 1.56 (1.29–1.89) 105 66 1.62 (1.12–2.33) 1.57 (1.33–1.86)
J01EA01 Trimethoprim 402 281 1.60 (1.33–1.92) 149 114 1.38 (1.03–1.84) 1.53 (1.31–1.79)
J01CE02 Phenoxymethylpenicillin 847 595 1.34 (1.20–1.50) 423 277 1.51 (1.29–1.77) 1.39 (1.27–1.53)
J01MA02 Ciproflolaxin 830 630 1.35 (1.19–1.52) 194 134 1.43 (1.10–1.86) 1.36 (1.22–1.52)
J01CA08 Pivmecillinam 535 422 1.21 (1.05–1.41) 309 211 1.45 (1.19–1.78) 1.29 (1.14–1.45)
Antiprotozoal drug
P01AB01 Metronidazole 169 185 0.73 (0.57–0.93) 51 51 0.60 (0.38–0.94) 0.70 (0.56–0.87)
Antithrombotic agents
B01AC24 Ticagrelor 96 14 5.14 (2.85–9.26) 27 6 3.12 (1.27–7.67) 4.42 (2.70–7.24)
B01AC04 Clopidogrel 1290 852 1.78 (1.57–2.01) 391 251 1.44 (1.19–1.76) 1.68 (1.51–1.86)
B01AB05 Enoxaparin 126 93 1.34 (0.98–1.83) 78 43 1.85 (1.14–3.00) 1.47 (1.13–1.92)
B01AC06 Acetylsalicylic acid 15489 15240 0.99 (0.95–1.03) 3141 2803 1.09 (1.02–1.17) 1.02 (0.98–1.05)
Antiadrenergic agents
R03AC03 Terbutaline 968 787 1.16 (1.04–1.30) 92 77 1.24 (0.89–1.73) 1.17 (1.05–1.30)
R03AC02 Salbutamol 618 526 1.12 (0.98–1.28) 653 532 1.16 (1.00–1.34) 1.14 (1.03–1.26)
Proton pump inhibitors
A02BC05 Esomeprazol 871 802 1.09 (0.96–1.25) 725 588 1.29 (1.13–1.48) 1.18 (1.08–1.30)
A02BC01 Omeprazole 8870 8261 1.12 (1.07–1.18) 238 213 1.17 (0.94–1.45) 1.12 (1.07–1.18)
Vasodilator
C01DA02 Glyceral trinitrate 5020 2949 1.84 (1.74–1.94) 1758 864 2.15 (1.96–2.36) 1.92 (1.83–2.01)
Prokinetic drug
A03FA01 Metoclopramide 709 503 1.49 (1.28–1.73) 335 220 1.40 (1.12–1.75) 1.46 (1.29–1.66)
Expectorant
R05CB01 Acetylcysteine 1677 1375 1.14 (1.05–1.24) 519 394 1.11 (0.96–1.30) 1.13 (1.05–1.22)
Anxiolytic
N05BA01 Diazepam 1165 957 1.12 (0.99–1.26) 664 575 1.06 (0.93–1.22) 1.09 (1.00–1.20)
Angiotension II antagonists
C09CA01 Losartan 1728 1738 0.95 (0.86–1.05) 292 310 0.89 (0.73–1.08) 0.94 (0.86–1.02)
C09CA06 Candesartan 1363 1448 0.88 (0.79–0.98) 360 387 0.92 (0.77–1.09) 0.89 (0.81–0.98)
Antidepressants
N06AB04 Citalopram 5548 5513 0.97 (0.90–1.05) 170 182 0.85 (0.66–1.11) 0.96 (0.89–1.03)
N06AB06 Sertraline 1358 1360 0.90 (0.78–1.04) 90 98 0.78 (0.53–1.13) 0.88 (0.77–1.01)
ACE inhibitor
C09AA05 Ramipril 1870 1855 0.92 (0.83–1.02) 709 683 0.94 (0.81–1.08) 0.93 (0.85–1.01)
Antigout agent
M04AA01 Allopurinol 1897 1952 0.93 (0.83–1.03) 351 394 0.85 (0.70–1.04) 0.91 (0.83–1.00)
Antidiabetic agent
A10BA02 Metformin 2659 2896 0.86 (0.79–0.94) 693 695 0.95 (0.83–1.09) 0.89 (0.82–0.95)
Beta-blocking agents
C07AB02 Metoprolol 8861 8437 1.05 (1.00–1.11) 2579 2289 1.11 (1.02–1.20) 1.07 (1.02–1.12)
Continued
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In online supplementary material, Tables S1 and S2, we present all drugs selected by BOLASSO in either 
Norway or Sweden, respectively. Apart from the results of the BOLASSO, we also present the univariable, 
non-penalized estimates for the selected drugs in these tables.
Sensitivity analysis. In online Supplementary Table S3, we present the results of our analyses where we 
extended the case-, control- and wash-out periods from 7 days to 14 days. Point estimates were generally similar 
to those in our main analyses. However, these analyses selected slightly more drugs. Some additional cardiovas-
cular drugs (vasodilator isosorbide mononitrate, diuretic bendroflumethiazide, beta-blocker bisoprolol) were 
associated with higher AMI risk; whereas others (angiotensin II antagonist valsartan, calcium channel blocker 
amlodipine, pravastatin, atorvastatin and diuretic spironolactone) were associated with lower risk. Some addi-
tional antibiotics (clindamycin and nystatin), opioid analgesics (ketobemidone in combination with antispas-
modics, fentanyl, tramadol), the anti-cancer drug capecitabine, the anxiolytic oxazepam and the antidepressant 
mirtazapine were also associated with increased risk. For norethisterone and estrogen, tolterodine, hydrocor-
tisone, budesonide, tiotropium bromide, salmeterol and fluticasone, we observed lower risk in the extended 
analyses.
In online Supplementary Table S4, we present analyses restricted to those AMI cases diagnosed in hospital. 
The results were largely similar to the main analyses, but BOLASSO selected fewer drugs, possibly due to the 
lower statistical power.
In online Supplementary Tables S5 and S6, we present sub-group analyses by age (dichotomized at 80 years) 
for 48 drugs selected via BOLASSO approach in both countries. Relative risks were generally comparable between 
the two age groups.
Discussion
In this pharmacopeia-wide association study, we investigated all possible associations between pharmaceutical 
drugs requiring a prescription and short-term risk for AMI using nationwide data from two countries, Norway 
and Sweden. We identified 48 drugs that were either associated with increase or decrease in short-term risk for 
AMI in both countries.
Our approach had similarities with genome-wide association studies, but also some important differences that 
are reflected in our analytic strategy. Bonferroni or similar adjustments are widely used in genome-wide associa-
tion studies to handle the problem of multiple comparisons. These methods adjust the p value or the significance 
level based on the number of tests performed and decrease the occurrence of false positive findings, albeit at the 
ATC CodeЅ Drug Names
Exposed Case- 
period only
Exposed 
Control- 
period only
Sweden‡
Exposed Case- 
period only
Exposed 
Control- 
period only
Norway§ Total
RR (95% CI) RR (95% CI)
Combined 
estimates RR 
(95% CI)
C07AB03 Atenolol 2836 2823 1.01 (0.93–1.09) 252 285 0.79 (0.65–0.96) 0.98 (0.91–1.05)
Calcium-channel blockers
C08CA01 Amlodipine 2512 2544 0.92 (0.85–1.00) 706 718 0.96 (0.85–1.09) 0.93 (0.87–1.00)
C08CA02 Felodipine 3529 3617 0.91 (0.85–0.98) 112 93 1.34 (0.96–1.87) 0.93 (0.86–0.99)
Decongestant
R01AD09 Mometasone 326 338 0.87 (0.73–1.03) 83 100 0.74 (0.54–1.03) 0.84 (0.72–0.98)
Diuretics
C03CA01 Furosemide 14307 13807 1.04 (0.99–1.09) 1317 1201 1.05 (0.95–1.17) 1.04 (1.00–1.09)
C03DA01 Spironolactone 2716 2674 0.94 (0.86–1.03) 258 219 1.17 (0.92–1.48) 0.97 (0.89–1.05)
Glucocorticoid
H02AB06 Prednisolone 3692 3486 1.05 (0.97–1.13) 963 823 1.05 (0.94–1.17) 1.05 (0.99–1.12)
Hypnotics and sedatives
N05CF01 Zopiclone 5999 6024 0.96 (0.90–1.02) 1618 1460 1.06 (0.97–1.17) 0.99 (0.94–1.04)
N05CF02 Zolpidem 2555 2564 0.97 (0.89–1.05) 175 191 0.85 (0.67–1.07) 0.96 (0.88–1.03)
Lipid modifying agent
C10AA01 Simvastatin 5611 5672 0.94 (0.88–0.99) 1806 1748 0.90 (0.82–0.98) 0.93 (0.88–0.97)
Antithyroid agent
H03AA01 Levothyroxine sodium 4843 4863 0.93 (0.86–1.01) 629 648 0.92 (0.80–1.06) 0.93 (0.87–1.00)
Antianemic agent
B03BA03 Hydroxocobalamin 125 155 0.79 (0.61–1.01) 49 63 0.66 (0.43–1.02) 0.76 (0.61–0.94)
Table 2. Relative risks of acute myocardial infarction within 7 days after the drug was dispensed, selected by 
BOLASSO approach† in both countries. *Case crossover analysis, case period (1 to 7 days) and control period 
(15 to 21 days) before the index-date for the diagnosis of AMI. †In BOLASSO, the effect of each selected drugs 
is controlled for the effect of other selected drugs. ‡Data from the Swedish Prescribed Drug Register, 2005 to 
2014. §Data from the Norwegian Prescription Database, 2004 to 2014. ‖Combined estimates of Norwegian and 
Swedish data calculated using fixed-effect model. SClassified according to Anatomical Therapeutic Chemical 
(ATC), 5th level.
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expense of increasing the occurrence of false negative findings. The Bonferroni method also assumes that associ-
ations are essentially random and tests a joint null hypothesis that no exposures are associated with the outcome. 
This might be justifiable for genome-wide association studies, where, at most, only a handful of true associations 
are likely out of millions of tested candidates. However, such a joint null hypothesis makes less sense in our study, 
because many medications clearly do influence AMI risk8. Finally, and most importantly, Bonferroni and related 
methods can increase the rate of true positive findings but cannot improve estimation. On the contrary, estimates 
for effects selected based on Bonferroni adjusted significance are likely to be substantially inflated. In contrast, 
penalized regression can greatly improve the accuracy of estimation over conventional methods in the setting of 
multiple comparisons9,10.
It may be useful to consider the medications that we found to be associated with AMI risk in several catego-
ries, based upon standard epidemiological principles. In contrast to GWAS, PWAS examines medications that 
vary frequently in time and bear specific indications, and hence are prone to confounding and other issues for 
which appropriate epidemiological cautions are necessary. First are cases in which reverse causation may be at 
play. This includes drugs specifically used to treat accelerating symptoms of myocardial ischemia such as analge-
sics, nitroglycerin or metoprolol, but also drugs used to treat conditions that produce chest pain or other ischemic 
symptoms, such as gastroesophageal reflux, anxiety attacks or respiratory conditions. This latter could explain the 
observed associations for proton pump inhibitors, antiadrenergic agents, and anxiolytics.
One approach to address reverse causation is comparison within a single drug class, where members usually 
have similar if not identical indications. Large differences between the observed associations for drugs within the 
same class might indicate true differences in cardiovascular effects. For example, morphine in combination with 
antispasmodics had a much stronger association with short-term risk of AMI than other opioids, suggesting that 
this combination could be a strong candidate for further in-depth studies that may eventually result in regulatory 
changes. Also, ticagrelor had a considerably stronger association with AMI risk than other antithrombotic agents, 
although this may reflect its narrower range of use, namely that is typically prescribed in the acute phases before 
and after AMI when the risk of recurrence is highest.
Second are cases of probable confounding. This particularly affects drugs used to treat conditions that them-
selves increase risk of AMI, such as antibiotics to treat infections and drugs to treat inflammatory or acute painful 
conditions that may increase risk similarly. Although these associations are unlikely to be causal, PWAS offers the 
particular advantage that it may, by proxy, identify important physiological pathways leading to AMI. Although 
infection has been associated with triggering of AMI in previous studies11, our much larger study provides a 
richer source of evidence for this hypothesis. Much like reverse causation, comparison within class, even for con-
founders, may yield important insights, and our results suggest that metronidazole may acutely lower risk of AMI. 
Suggestively, this may reflect the disulfiram-like activity of metronidazole, given the association of acute alcohol 
intake with AMI12 and the absence of other commonly-used drugs that inhibit aldehyde dehydrogenase activity. 
Alternatively, animal and in vitro studies have suggested that pathogens such as helminths might protect against 
atherosclerosis via activation of the Th2 pathway13,14. This could imply that the association of metronidazole with 
a lower risk of AMI might reflect a cardioprotective effect of an underlying parasitic infection. However, given the 
broad range of indications for metronidazole, further study of this possibility is needed.
Third are true associations in which drugs may causally influence AMI risk. This group includes drugs that 
plausibly increases or decreases risk themselves and, equally, in which withdrawal of an existing medication 
increases risk. The latter mechanism is the most plausible explanation for the inverse association with AMI for 
statins, calcium-channel blockers, angiotensin II antagonists and angiotensin-converting-enzyme inhibitors. 
Our results suggest that clinicians should exercise caution in withdrawing these medications to avoid rebound 
increases in risk. The inverse associations between AMI risk and some antidepressants, allopurinol and met-
formin were also expected based on prior epidemiological studies15–18 and the known pathophysiological effects 
of these drugs. For example, SSRIs possess acute anti-platelet effects19, allopurinol seems to reduce oxidative 
stress, to prevent plaque instability and to have anti-ischemic properties20 and metformin may improve endothe-
lial function21. However, our results provide large-scale evidence of associations that extend to triggering of clin-
ical events.
Lastly, PWAS has the potential to identify new, unexpected agents, where the mechanism of action is uncer-
tain but that clearly require further study. The inverse associations between AMI risk and use of hydroxocobala-
min, levothyroxine and mometasone are examples for such unexpected and unexplained findings in the present 
study. We are not aware of earlier studies suggesting acute cardioprotection for these drugs; neither can these 
associations be readily explained by the indication nor by the known effects of these drugs. It is possible that they 
are markers of clinical stability and only prescribed when patients are at particularly low risk, but further clinical 
detail would be needed to explore this possibility.
To the best of our knowledge, only two studies, one from the United States22 and another from Europe23 
have adopted somewhat similar approaches and investigated the association between drugs and AMI in a 
hypothesis-free manner. In contrast to our study, the data from these prior studies were not nationwide, but relied 
on databases of administrative claims24, and the endpoint of AMI was not based on a clinical diagnosis in a hospi-
tal. None of the studies applied a case-crossover design. Furthermore, these studies used Bonferroni adjustment 
for multiple comparisons. Thus, the effect sizes were not comparable with those in our study. However, overall, 
the group of drugs selected as being associated with AMI risk in these two earlier studies were generally similar to 
those in our study, further supporting the value of this approach as a reproducible method potentially appropriate 
for standardization, automation, and continuous monitoring of sentinel events within national health systems. In 
this regard, our approach fits within the rubric of adaptive biomedical innovation, which seeks to apply real-time, 
large-scale, rapid-cycle clinical data to the process of approving, monitoring, and targeting new pharmaceuticals, 
devices, and other forms of therapy25.
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Strength and limitations. We conducted a nation-wide study in two countries where health care systems 
are universal and equally accessible to virtually all the residents. Reporting is mandatory in the patient registers, 
cause of death registries and prescription databases in both Norway and Sweden. Therefore, our study is not sub-
ject to bias due to self-selection or to recall bias. Validation studies confirm that the quality of information in the 
Norwegian and Swedish Patient Registers is very high on AMI26,27. Furthermore, the prescription databases in 
both countries are fully digitalized, and hence little chance of misclassification of drug retrieval exists. Due to the 
case-crossover design, our results are unlikely to be confounded by stable patient characteristics, chronic condi-
tions or lifestyle related factors predisposing to AMI and influencing medication use28, although they are prone to 
confounding by characteristics that fluctuate within individuals over days-to-weeks.
Apart from these strengths, our study also has important limitations. Although we used a BOLASSO to mini-
mize the problem of multiple comparisons and relied on nation-wide data from two countries, but nonetheless we 
cannot rule out the possibility that some associations are due to chance and further studies are needed to confirm 
the findings from this large-scale screening. This limitation is common to all broad-based, agnostic screening 
approaches. Similar to GWAS, our study should be regarded as a first step in monitoring the pharmacopoeia, 
with direct clinical impact occurring later. For example, the first GWAS on age-related macular degeneration was 
conducted in 200529, and it eventually led to promising therapies for age-related macular degeneration in 201630.
Given the exploratory nature of our work, we analyzed all drugs in a uniform way and consequently the 
hypothesized case-, control- and wash-out periods might not be optimal for several drugs. It is important to 
recognize that such uncertainties lead to a bias towards null in a case-crossover study28,31. Thus, under- but not 
overestimation of effects is likely in case of some drugs due to the suboptimal length of time windows. It is impor-
tant to emphasize, however, that when we extended the case-, control- and wash-out periods in our sensitivity 
analyses, we observed generally similar results. Also, case-crossover studies are prone to the so-called ‘persistent 
user bias’7 which might lead to an upward bias of the estimates in case of chronically-used drugs. As this study 
lacks data to distinct between medications for acute use and chronic use. Thus, these results must be interpret 
cautiously on clinical grounds; particularly those prescribed drugs that are used chronically. However, it cannot 
explain the novel findings in this study, such as the observed protective effect of hydroxocobalamin, levothyroxine 
and mometasone, nor to differences within class. Also, given the register-based nature of our study, we do not 
have additional information on patient characteristics such as cardiovascular risk factors or previous cardiac 
events, although our use of the case-crossover design precludes confounding by stable personal characteristics.
Finally, Norwegian Prescription Database and Swedish Prescribed Drug Register contain complete and valid 
information on dispensed drugs, but they do not describe the actual date of self-administration. This most proba-
bly led to a non-differential misclassification and a bias toward null findings. In this regard, claims-based datasets 
may have potential advantages for extending and refining this approach.
In summary, this pharmacopeia-wide association study demonstrates the feasibility and results of a system-
atic, unbiased approach to pharmacological triggers of AMI. Our results also highlight the value of rigorous 
epidemiological consideration of observed findings. This approach also offers the possibility of routine, rigorous 
monitoring of the worldwide pharmacopeia for agents that trigger, or prevent the triggering of, serious acute 
health events.
Methods
Study design. We applied a case-crossover design28,31, which includes only cases of a disease and applies 
self-matching by comparing exposure before the disease onset with disease-free time in the past as control infor-
mation. This design is a special case of the conventional matched case-control design, and it has common features 
with cross-over trials. A primary advantage of the case-crossover design is that stable within-person characteris-
tics cannot confound observed associations, although time-varying features can. Today, it is largely considered a 
standard method to study acute or triggering effects of transient exposures on serious outcomes such as AMI32–34.
Ascertainment of AMI. We used the Norwegian Patient Registry, the Swedish National Patient Registry, and 
cause of death registries in Norway and Sweden to identify AMI cases35,36. Validation studies show that the quality 
of information on AMI in these registers, especially in the Norwegian Patient Registry and the Swedish National 
Patient Register is very high26,27. In Norway, all patients with primary ICD-10 hospital discharge diagnoses of I21 
or I22 from 1 January 2008 to 31 December 2014 were included, as were individuals with a comparable cause of 
death from 1 January 2004 to 31 December 2014. In Sweden, the corresponding dates for both the hospital diag-
nosis and cause of death were between 1st November 2005 and 31st December 2014. For each individual, only the 
first registered episode of AMI was included in the analyses.
Prescribed medications. We assessed the risk of AMI associated with each and every drug prescribed 
to AMI patients. Data on dispensed medications prior to the occurrence of AMI were abstracted from the 
nation-wide registration of dispensed drugs in Norway and Sweden, respectively. The Norwegian Prescription 
Database was established in 200437. All Norwegian pharmacies are required to supply information from pre-
scriptions including type and dosage of the drug and date of drug dispense. Sweden has also established a similar 
register, the Swedish Prescribed Drug Register in 200538. A personal identifier is attached to these data that makes 
it possible to link the information on drug use to other health related registers existing in these countries. The 
prescription databases do not include information on drugs purchased over-the-counter, or given to institution-
alized patients in nursing homes or hospitals. In Norway, it was possible to exclude participants who, at the time 
of AMI, were institutionalized and for whom registration of dispensed medications was not available. In Sweden, 
in the absence of this information, we included only those patients who had at least one drug prescribed during 
one year before the occurrence of AMI.
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Statistical analyses. For each patient, the occurrence of drug dispensing within 1 to 7 days before the date 
of diagnosis of AMI (case period) was compared to a time window of 15 to 21 days before the AMI diagnosis 
(control period) for each drug individually. To minimize the carryover effects of drugs, we included a one-week 
wash-out period between the case- and the control-periods. We calculated odds ratios together with 95% con-
fidence intervals, comparing the odds of drug dispensed in the case period to that in the control period using 
conditional logistic regression.
We assessed all prescribed medications in relation to AMI risk. Because our aim was to identify drugs with a 
real effect and to assess the size of these effects, we opted not to use Bonferroni adjustment and similar conven-
tional methods to address the problem of multiple comparisons inherent to such settings, as they fail to estimate 
the size of these associations correctly10. Instead, we applied a version of the least absolute shrinkage and selec-
tion operator (LASSO) regression analysis9,10,39–41 called BOLASSO (bootstrap-enhanced least absolute shrinkage 
operator)42. With the BOLASSO, a number of bootstrap samples are drawn from the dataset, where each boot-
strap sample is generated by sampling N pairs (N is the total number of drugs in the dataset) with replacement. 
Here, we have drawn 1000 bootstrap samples. Of note, confidence intervals generated via BOLASSO approach are 
not optimal, because each bootstrap sample is estimated on different penalty parameters. Therefore, some of the 
drugs selected by this approach may include one in their confidence interval. In online supplementary material, 
Appendix A, we present in detail the background of the method and how we implemented BOLASSO in condi-
tional logistic regression models for case-crossover data.
We conducted separate analyses for Norwegian and Swedish data. We presented both country-specific and 
combined estimates for drugs selected by BOLASSO from both countries. In BOLASSO, the effect of each 
selected drug is controlled for the effects of all other selected drugs. The combined estimates were calculated 
using fixed-effect models43.
We performed sensitivity analyses to examine the robustness of our results. Firstly, we extended the case-, 
control- and wash-out periods from 7 days to 14 days (case period = 1 to 14 days; control period = 29 to 42 days) 
and repeated all analyses. Secondly, because a diagnosis of AMI is likely to be more reliable when given at a 
hospital than when provided as a cause of death, we also repeated our main analyses when we excluded patients 
who died outside of hospital. Lastly, we performed subgroup analyses by age (dichotomized at 80 years) on drugs 
selected by BOLASSO approach in both the countries. Separate analyses were performed for Norwegian and 
Swedish data.
All statistical analyses were performed using R (version 3.2.3; R foundation for Statistical Computing, Vienna, 
Austria) and Stata/IC 14 (Stata Corp, College Station, Texas, USA).
Ethical approval and informed consent. Informed consent for study participation was obtained by the 
national registers from the respective country. The data for the patients from the respective registers was send to 
us anonymously. Thus, in our present research, no patients were involved in setting the research question or the 
outcome measures, nor were they involved in developing plans for recruitment, design, or implementation of the 
study. No patients were asked to advise on interpretation or writing up of results.
The studies were approved by the Regional Committees for Medical and Health Research Ethics (REC) in 
Central Norway and Regional Ethical Review Board in Sweden. In addition, Norwegian data was also approved 
by Norwegian Data Protection Authority (Datatilsynet). All methods were performed in accordance with the 
relevant guidelines and regulations by the respective ethical committees from both Norway and Sweden.
Data Availability
The data that support the findings of this study are available from the Norwegian Patient Registry, Norwegian 
Prescription database, Norwegian Cause of Death Registry, and Swedish National Patient Registry, Swedish Pre-
scribed Drug Registry, Swedish Cause of Death Registry but restrictions apply to the availability of these data, 
which were used under license for the current study, and so are not publicly available. Data are however available 
from the corresponding authors upon reasonable request and with permission of respective national registry in 
Norway and Sweden.
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